> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Revises EUAs for Covid Serial Testing
- URL: https://www.fdaweb.com/fda-revises-euas-for-covid-serial-testing/
- Published: 2022-11-01T12:00:00.000Z
- Updated: 2026-09-14T18:04:44.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5153106

FDA has revised the authorized uses for, and is requiring updates to product labeling regarding repeat, or serial, testing, for all currently authorized SARS-CoV-2 antigen tests. An 11/1 revised “[Letter of Authorization](https://www.fda.gov/media/162799/download?ref=fdaweb.com)” creates one additional Condition of Authorization and also eliminates an earlier condition that it says is no longer needed.

The updates are in response to available performance data on Covid-19 antigen tests showing that repeat testing after a negative Covid-19 antigen test result increases the chance of an accurate result in people with and without symptoms and could help prevent people from unknowingly spreading the virus to others.

The revision requires test developers to take certain actions, including submitting a supplemental EUA request to the agency with updated labeling to reflect the revised authorized uses, as follows:

- Where a test was previously authorized for testing of symptomatic individuals (for example, within the first \[number specific to each test\] days of symptom onset), the test is now authorized for use at least twice over three days with at least 48 hours between tests.
- Where a test was previously authorized for testing of asymptomatic individuals (for example, individuals without symptoms or other epidemiological reasons to suspect Covid-19), the test is now authorized for use at least three times over five days with at least 48 hours between tests.